Signadori Bio appoints Dr. Selwyn Ho, MB BS as Chief Executive Officer to lead company into next stage of growth
Signadori Bio, a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours, today announced the appointment of Dr. Selwyn Ho as Chief Executive Officer.
Sofinnova Partners and Gustave Roussy launch first biotech company through Strategic Partnership
Sofinnova Partners, a leading European life sciences venture capital firm, in collaboration with Gustave Roussy, Europe’s leading cancer center, announces the creation of their first pioneering biotech company.
